⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VSTM News
Verastem, Inc.
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
businesswire.com
VSTM
Verastem Oncology to Present at Jefferies Healthcare Conference
businesswire.com
VSTM
Form 8-K
sec.gov
VSTM
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
businesswire.com
VSTM
Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026
businesswire.com
VSTM
Verastem Oncology to Present at Upcoming Investor Conferences
businesswire.com
VSTM
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
businesswire.com
VSTM
Form 8-K
sec.gov
VSTM
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
businesswire.com
VSTM
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
businesswire.com
VSTM